Spots Global Cancer Trial Database for malignant solid tumour
Every month we try and update this database with for malignant solid tumour cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | NCT02843204 | Malignant Solid... | Pembrolizumab NK immunotherap... | 18 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors | NCT00551096 | Malignant Solid... Biliary Cancer Pancreatic Canc... | Gemcitabine Capecitabine ZD6474 | 18 Years - | University of Colorado, Denver | |
| Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | NCT00388427 | Malignant Solid... | Dasatinib (BMS-... Cetuximab (Erbi... | 18 Years - | University of Pittsburgh | |
| Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | NCT01554371 | Malignant Solid... Breast Cancer N... Neuropathy | Eribulin Cyclophosphamid... | 18 Years - 80 Years | University of California, San Francisco | |
| Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | NCT01309490 | Malignant Solid... | Ribavirin | 18 Years - | Jewish General Hospital | |
| Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation | NCT02786628 | Malignant Solid... Hematologic Mal... Planned Hematop... | Physical perfor... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors | NCT02853903 | Malignant Solid... | NK immunotherap... | 30 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| BN80927 in Patients With Advanced Malignant Solid Tumors | NCT01435096 | Malignant Solid... | BN80927 | 18 Years - | Ipsen | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours | NCT01721148 | Malignant Solid... | ASLAN002( BMS 7... | 18 Years - | ASLAN Pharmaceuticals | |
| Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors | NCT02923466 | Malignant Solid... | VSV-IFNβ-NIS VSV-IFNβ-NIS an... | 18 Years - | Vyriad, Inc. | |
| Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors | NCT01184807 | Malignant Solid... | OPB-51602 | 21 Years - | Otsuka Beijing Research Institute | |
| A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors | NCT01325558 | Locally Advance... Malignant Solid... | ALT-836 in comb... | 18 Years - | Altor BioScience | |
| Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | NCT01343498 | Malignant Solid... | BEZ235 | 18 Years - | SCRI Development Innovations, LLC | |
| Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | NCT02843204 | Malignant Solid... | Pembrolizumab NK immunotherap... | 18 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | NCT01598129 | Malignant Solid... | ONCOS-102 | 18 Years - | Targovax ASA | |
| Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | NCT01337505 | Malignant Solid... | INNO-206 | 18 Years - 70 Years | ImmunityBio, Inc. | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | NCT02857920 | Malignant Solid... | Bevacizumab NK immunotherap... | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | NCT01618136 | Malignant Solid... Ovarian Cancer Triple Negative... Advanced Melano... B-cell Malignan... | E7449 alone E7449 plus TMZ E7449 plus carb... | 18 Years - | Eisai Inc. | |
| ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | NCT01598129 | Malignant Solid... | ONCOS-102 | 18 Years - | Targovax ASA | |
| BN80927 in Patients With Advanced Malignant Solid Tumors | NCT01435096 | Malignant Solid... | BN80927 | 18 Years - | Ipsen | |
| Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors | NCT02843204 | Malignant Solid... | Pembrolizumab NK immunotherap... | 18 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours | NCT01951846 | Malignant Solid... | BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | NCT01618136 | Malignant Solid... Ovarian Cancer Triple Negative... Advanced Melano... B-cell Malignan... | E7449 alone E7449 plus TMZ E7449 plus carb... | 18 Years - | Eisai Inc. | |
| Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | NCT00635791 | Malignant Solid... Renal Cell Carc... Non Small Cell ... | Sorafenib Vorinostat | 18 Years - | University of Colorado, Denver | |
| Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors | NCT01286896 | Malignant Solid... | Sunitinib | 18 Years - | The Netherlands Cancer Institute | |
| Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer | NCT00801151 | Malignant Solid... | Zolinza (vorino... | 18 Years - | Institut Claudius Regaud | |
| Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | NCT01023737 | Malignant Solid... | Hydroxychloroqu... Vorinostat | 16 Years - | The University of Texas Health Science Center at San Antonio | |
| Long-Term Compassionate Use Study for Continued Administration of SCB01A-01 | NCT01151930 | Malignant Solid... | SCB01A | 18 Years - | SynCore Biotechnology Co., Ltd. | |
| ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | NCT01598129 | Malignant Solid... | ONCOS-102 | 18 Years - | Targovax ASA | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | NCT01023737 | Malignant Solid... | Hydroxychloroqu... Vorinostat | 16 Years - | The University of Texas Health Science Center at San Antonio | |
| Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | NCT01376505 | Malignant Solid... Breast Cancer Malignant Tumor... GIST Ovarian Cancer | HER-2 vaccine Extension HER-2... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Long-Term Compassionate Use Study for Continued Administration of SCB01A-01 | NCT01151930 | Malignant Solid... | SCB01A | 18 Years - | SynCore Biotechnology Co., Ltd. | |
| Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients | NCT01309490 | Malignant Solid... | Ribavirin | 18 Years - | Jewish General Hospital | |
| Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors | NCT01286896 | Malignant Solid... | Sunitinib | 18 Years - | The Netherlands Cancer Institute | |
| Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | NCT02857920 | Malignant Solid... | Bevacizumab NK immunotherap... | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | NCT00388427 | Malignant Solid... | Dasatinib (BMS-... Cetuximab (Erbi... | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
